Matches in Wikidata for { <http://www.wikidata.org/entity/Q65379801> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q65379801 description "clinical trial" @default.
- Q65379801 description "ensayu clínicu" @default.
- Q65379801 description "klinisch onderzoek" @default.
- Q65379801 description "клінічне випробування" @default.
- Q65379801 name "TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors" @default.
- Q65379801 name "TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors" @default.
- Q65379801 type Item @default.
- Q65379801 label "TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors" @default.
- Q65379801 label "TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors" @default.
- Q65379801 prefLabel "TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors" @default.
- Q65379801 prefLabel "TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors" @default.
- Q65379801 P1132 Q65379801-BAF19A1A-049B-404B-B7A7-6A7888815EA7 @default.
- Q65379801 P131 Q65379801-2C190E61-43E9-4E72-91A0-EDA71E0DB866 @default.
- Q65379801 P1476 Q65379801-D39EA235-51C2-467E-91E3-8F1A7D2DA7A6 @default.
- Q65379801 P17 Q65379801-01730BB6-A393-4D92-BDB3-370AE3AD48A3 @default.
- Q65379801 P17 Q65379801-269F6AAB-6B6D-4541-B6EE-A114C5D2E569 @default.
- Q65379801 P17 Q65379801-2941FF47-E7BB-403E-B756-BB368CDC53F7 @default.
- Q65379801 P17 Q65379801-2BABD40B-7EAB-4297-944C-CB4B6EE1F094 @default.
- Q65379801 P17 Q65379801-4DA5731A-B286-43CC-9ECF-FF17D2F2190A @default.
- Q65379801 P17 Q65379801-65A9C1F7-C055-4125-92A2-A8FD45E46310 @default.
- Q65379801 P17 Q65379801-9947B143-9915-45A1-BD2F-373D3EC62DFF @default.
- Q65379801 P17 Q65379801-A0E995D8-896C-48D5-88D7-679D1E78F44D @default.
- Q65379801 P17 Q65379801-AA40094D-886B-4860-B71E-9BF92E333251 @default.
- Q65379801 P17 Q65379801-B0176099-1DE4-47B1-B933-F054E92D40A9 @default.
- Q65379801 P17 Q65379801-B3A0E180-1BEC-459F-8412-B81998618B9A @default.
- Q65379801 P17 Q65379801-BCB53DF0-806D-4168-A4CE-F9B571E90A86 @default.
- Q65379801 P17 Q65379801-BE37E417-3824-4BD5-9FFF-90BEB86E5261 @default.
- Q65379801 P17 Q65379801-C1AD67E9-BD50-45D6-9C84-1F4DF80A9600 @default.
- Q65379801 P17 Q65379801-D4FEAF49-7F60-4DD5-A776-14F3A396ABC9 @default.
- Q65379801 P17 Q65379801-ED9ABF02-FECF-4AC3-8DE1-A5613320AEAA @default.
- Q65379801 P17 Q65379801-F620F2F5-4AFE-4015-B3CD-A3861196EDC4 @default.
- Q65379801 P2899 Q65379801-7A6A38C8-6CBF-4248-8045-2F02AD7786DF @default.
- Q65379801 P3098 Q65379801-F159AB64-AB18-4FD8-970C-74398B0BC76A @default.
- Q65379801 P31 Q65379801-05D70ECE-BD05-400B-B4B6-6997F67CAF0C @default.
- Q65379801 P4135 Q65379801-BFB4DCEB-AA6B-49A7-804E-E53B2E88C1CC @default.
- Q65379801 P4844 Q65379801-97598F23-EA0E-426E-84E6-4F0871420F7F @default.
- Q65379801 P580 Q65379801-FFB1B0CB-45A2-4D31-97E2-F3CE8009F24D @default.
- Q65379801 P582 Q65379801-D84C90AF-3854-4552-84FE-3FDFB68EAAA0 @default.
- Q65379801 P6099 Q65379801-8B88F71C-7870-4A5D-8E81-9F759122DF84 @default.
- Q65379801 P8363 Q65379801-2F1183E5-845B-43B2-9D22-CF58D9BC8ED8 @default.
- Q65379801 P1132 "+680" @default.
- Q65379801 P131 Q1183 @default.
- Q65379801 P1476 "A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects." @default.
- Q65379801 P17 Q142 @default.
- Q65379801 P17 Q145 @default.
- Q65379801 P17 Q155 @default.
- Q65379801 P17 Q16 @default.
- Q65379801 P17 Q183 @default.
- Q65379801 P17 Q258 @default.
- Q65379801 P17 Q29 @default.
- Q65379801 P17 Q298 @default.
- Q65379801 P17 Q30 @default.
- Q65379801 P17 Q31 @default.
- Q65379801 P17 Q408 @default.
- Q65379801 P17 Q45 @default.
- Q65379801 P17 Q668 @default.
- Q65379801 P17 Q800 @default.
- Q65379801 P17 Q804 @default.
- Q65379801 P17 Q869 @default.
- Q65379801 P17 Q96 @default.
- Q65379801 P2899 "+18" @default.
- Q65379801 P3098 "NCT00543725" @default.
- Q65379801 P31 Q30612 @default.
- Q65379801 P4135 "+99" @default.
- Q65379801 P4844 Q421547 @default.
- Q65379801 P580 "2008-06-01T00:00:00Z" @default.
- Q65379801 P582 "2010-01-01T00:00:00Z" @default.
- Q65379801 P6099 Q42824827 @default.
- Q65379801 P8363 Q78089383 @default.